Developing new treatments for oral cancer pain
Official title: SPIGELMAN (UCLA) - MCSP- EXPLORATORY CHEMISTRY (EC)
Funded at Albany Molecular Research, INC. · NIH-10949389 · Data updated 2026-11-12
This study is working on developing new medications to help people with oral cancer manage their pain better, so they can find relief and improve their quality of life.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albany Molecular Research, INC. NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project start | August 18, 2023 |
| Project end | February 17, 2028 |
| Funding year | 2023 |
| Award (this year) | $662,120 |
| NIH project number | 271201800001I-0-759502300003-1 |
| Project ID | NIH-10949389 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing pain due to oral cancer or those with substance use disorders related to pain management.
✕Less likely to help
Patients with non-cancer-related pain or those not experiencing significant pain may not benefit from this research.
What this research studies
This research focuses on creating new medications to help manage pain associated with oral cancer. It involves a detailed process of medicinal chemistry, where scientists will design and synthesize new compounds, test their effectiveness, and analyze how they are absorbed and processed in the body. The goal is to identify novel inhibitors that can effectively target pain pathways and potentially address substance use disorders. Patients may benefit from innovative pain management options that arise from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective pain relief options for patients suffering from oral cancer.
How similar studies have gone: Other research initiatives have shown promise in developing new pain management therapies, indicating potential success for this approach.
Where this research is happening
-
Albany Molecular Research, INC.
Albany, United States Active
Researchers
- Principal investigator: Surman, Matthew — Albany Molecular Research, INC.
- Study coordinator: Surman, Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.